SEC Form 4 · accession 0001209191-15-024834
Kura Oncology, Inc. · KURA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Pappajohn
Officer — President · Director · 10% Owner
Period of report
Mar 6, 2015
Accepted (ET)
Mar 10, 2015 · 6:23 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001422143
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.0001 per shareF1 | Mar 6, 2015 | D | 2,000,000 | — | D | 0 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On March 6, 2015, Kura Oncology, Inc. (formerly Zeta Acquisition Corp. III) (the "Issuer") and the stockholders of the Issuer (the "Sellers") entered into a Redemption Agreement (the "Agreement"). Pursuant to the Agreement, the Issuer re-purchased and redeemed from Mr. Pappajohn 2,000,000 shares of Common Stock (the "Shares") for a purchase price equal to twenty-eight thousand dollars ($28,000). The purchase and sale of the Shares took place at a closing on March 6, 2015 immediately following the effectiveness of the merger transaction (the "Merger") contemplated by the Agreement and Plan of Merger, dated March 6, 2015, among the Issuer, Kura Oncology, Inc, and Kura Operations, Inc., a wholly-owned subsidiary of the Issuer.